~~<i id='55CAA795BF'><strike id='55CAA795BF'><tt id='55CAA795BF'><pre id='55CAA795BF'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

Wikipedia

author：hotspot 2025-09-02 09:57:15 - browse：74463

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： ChatGPT in medicine: STAT answers readers' burning questions

knowledge

explore

hotspot

leisure time

focus

explore

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

WSS

Medicare drug price lawsuits could be good politics for Biden

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Alkermes shareholders re

Maisha Meds is a PBM, but don't call it that

As demand for Covid shots wanes, Moderna seeks its next success

Medicare bonuses could stop drug shortages under Senate plan

hotspot

Wikipedia

knowledge

Cancer drug shortages should be causing more outrage

State Dept. review finds Biden bears some blame for Afghanistan failures

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medicare proposal to cover medical devices draws a mixed reaction

As demand for Covid shots wanes, Moderna seeks its next success

Duchenne breakthrough therapy leaves behind pioneering families

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

DIEP, the 'gold standard' of breast reconstruction, is under threat

Apple is now the first public company to be valued at $3 trillion

Medicare drug price lawsuits could be good politics for Biden

explore

Anesthesiologist group: stop taking Ozempic before surgery

A pediatrician calls for Congress to pass the child tax credit deal

Walensky prepares to leave CDC — and Congress — behind

Moonlake's readout produced a cash windfall. Risks remain

Activists slam private health insurers over coverage restrictions

The high cost of giving birth even with insurance

hotspot

leisure time

focus

explore